Lowest Price Guaranteed From USD 4,499
Published
October 2019
Pages
271
View Count
16920
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
[COVID-19 SERIES] The market for needle-free injection systems is expected to grow from $153 million to $717 million by 2030, at an annualized rate of 15%. In addition, the market for microneedle devices is expected to grow from around $40 million in 2025 to $206 million by 2030, at an annualized rate of close to 39%. Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to be among the leading causes of death and disability across the world. The Center for Managing Chronic Disease at the University of Michigan recently reported that over 50% of the global population is suffering from some form of chronic disease. Despite significant advances in drug / therapy development for the treatment of chronic diseases, there are several concerns related to the delivery of such therapeutics. Since most medications are developed for parenteral delivery, dosing errors and accidental needlestick injuries are some of the primary areas of concern. In fact, needle phobia is officially recognized as a medical condition by the American Psychiatric Association in its Diagnostic and Statistical Manual of Mental Disorders and is known to affect nearly 10% of the population. The Needlestick Safety and Prevention Act, which was signed into law in the US in November 2000, encouraged the development of a variety of needleless syringes / safety syringes, such as needle-free injection systems, microneedle patches and microneedle pens. A sustained focus towards self-injection has also facilitated significant advances in drug development and administration. In fact, the self-injection devices market is characterized by the presence of a myriad of advanced and innovative drug delivery solutions, such as (in alphabetical order) autoinjectors, jet injectors, large volume wearable injectors, microneedles, pen injectors, needleless syringes and prefilled syringes. In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19), where medical centers may not be equipped to deal with large masses for delivery of therapeutic / preventive vaccines (once these get approved).
The concept of needle free drug delivery is realized using a variety of actuation mechanisms (such as spring- or gas-powered devices) that are capable of facilitating the delivery of therapeutic interventions without the use of needles. On the other hand, microneedles are extremely minute needles (of the order of a few micrometers), which are designed to deliver drugs across the dermis. It is worth highlighting that such delivery systems are primarily based on the subcutaneous / intradermal and transdermal routes. The field of needleless drug delivery continues to witness significant advances, in terms of innovation in drug / therapy administration (such as dose tracking and real-time updates) and the development of compatible drug formulations. As a result, several stakeholders in the healthcare industry have developed interest in this upcoming field, and have launched product development / commercialization initiatives in the recent past.
The “Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with the needle-free injection systems and microneedles market, over the next 10-12 years. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for needle-free injection systems and microneedle devices. Based on various parameters, such as number of marketed / pipeline products, existing price of devices (for commercially available products only) and estimated annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. For needle-free injection systems, the report also features the likely distribution of the current and forecasted opportunity across [A] different types of actuation mechanisms (spring-based, gas powered and others), [B] routes of administration (subcutaneous, intramuscular and intradermal), [C] target disease indication (infectious diseases, diabetes, pain disorders and others), [D] product usability (disposable and re-usable) and [E] key geographical regions (North America, Europe, Asia and Rest of the World). Similarly, the projected future opportunity for microneedle devices has been analyzed across [A] various types of microneedle devices (hollow, solid and dissolving), [B] target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), [C] type of intervention (vaccines, therapeutic agent and others), and [D] key geographical regions (North America, Europe, Asia and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the needle-free injection systems and microneedle devices market and describes its evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to needle-free injection systems and microneedles, highlighting the growing demand for devices that enable painless administration of medication in the homecare setting. The chapter emphasizes the need for such devices, specifically in terms of the rising incidence and prevalence of chronic diseases. Subsequently, it provides an overview of the different types of needle free injectors and microneedles, listing their specifications and varied mechanisms of action. It also features a brief discussion on the challenges related to the R&D efforts associated with such healthcare, offering insights on anticipated future trends.
Chapter 4 provides a detailed overview of the overall landscape of needle-free injection systems that are developed / being developed for administration of various drug products. It features an in-depth analysis of the devices, based on a number of parameters, such as details on intellectual property portfolio, current status of development, route of administration (subcutaneous / intradermal / intramuscular), actuation mechanism (spring-based, gas-powered and others), type of load (liquid and solid), usability (single use and multiple use), capacity of the device (in terms of drug volume) and target disease areas. In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.
Chapter 5 provides a detailed overview of the overall landscape of microneedle devices that are developed / being developed for administration of various drugs. It features an in-depth analysis of the devices, based on a number of parameters, such as development status of various products (under development and commercialized), details on intellectual property portfolio, type of microneedle device (hollow, solid and dissolving), route of administration (subcutaneous, transdermal, intradermal and others), microneedle length and target disease areas. In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.
Chapter 6 features a product competitiveness analysis of needle-free injection systems and microneedles, based on the supplier power and product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 7 provides detailed profiles of key needle-free injection systems and microneedle device developers. Each profile presents a brief overview of the company, financial information (if available), product portfolio and recent developments.
Chapter 8 features a detailed analysis of needle-free injection systems and microneedles based on the AC (attractiveness versus competitiveness) matrix framework. It also includes a discussion on the relative market attractiveness and competitive strength of these devices. The purpose of the analysis is to enable companies to analyze their respective technical expertise, develop informed growth strategies (with respect to technical strength), and also make decisions related to acquiring new technologies or divesting the outdated ones.
Chapter 9 includes a brief case study on the role of contract manufacturing organizations that offer services for medical devices with emphasis on drug delivery devices. The chapter also features a discussion of the various challenges associated with medical device manufacturing and regulatory guidelines for medical devices. In addition, the chapter presents a region-wise mapping of the developers of the needle-free injection systems and microneedles with the availability of medical device contract manufacturers.
Chapter 10 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via needle-free injection systems in the future. The list was compiled considering various parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard / weight dependent), expected patent expiry (relevant only for marketed drugs) and product sales (relevant only for marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via needle free injectors and microneedles in the future was estimated using the weighted average of the aforementioned parameters.
Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via microneedle devices in the future. The list was compiled considering various parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard / weight dependent), expected patent expiry (relevant only for marketed drugs) and product sales (relevant only for marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via needle free injectors and microneedles in the future was estimated using the weighted average of the aforementioned parameters.
Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of needle free injectors and microneedles, till the year 2030. We have segregated the opportunity of needle-free injection systems on the basis of different types of actuation mechanisms (spring-based, gas powered and others), routes of administration (subcutaneous, intramuscular and intradermal), target disease indication (infectious diseases, diabetes, pain disorders and others), product usability (disposable and re-usable) and key geographical regions (North America, Europe, Asia and Rest of the World). Similarly, the projected future opportunity for microneedle devices has been analyzed across various types of microneedle devices (hollow, solid and dissolving), target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), type of intervention (vaccines, therapeutic agent and others), and key geographical regions (North America, Europe, Asia and Rest of the World).
Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Michael Schrader (CEO and Founder, Vaxess Technologies), Patrick Anquetil (CEO, Portal Instruments) and Henry King (Market Intelligence and Business Development Manager, Innoture).
Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the drug delivery devices industry.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Conventional Parenteral Drug Delivery
3.2.1. Needlestick Injuries
3.2.2. Incidence and Cost Burden Related to Needlestick Injuries
3.3. Minimally Invasive Drug Delivery
3.3.1. Key Drivers of Minimally Invasive Drug Delivery Systems
3.3.1.1. Rising Burden of Chronic Diseases
3.3.1.2. Healthcare Cost Savings
3.3.1.3. Need for Immediate Treatment in Emergency Situations
3.3.1.4. Growing Injectable Drugs Market
3.3.1.5. Need for Improving Medication Adherence
3.4. Needle-Free Injection Technology
3.4.1. Key Components of Needle-Free Injection Systems
3.4.1.1. Injection Device
3.4.1.2. Nozzle
3.4.1.3. Pressure Source
3.4.2. Operating Mechanism of Needle-Free Injection Systems
3.4.3. Classification based on Type of Load
3.4.3.1. Powder-based Injectors
3.4.3.2. Liquid-based Injectors
3.4.3.3. Depot Projectile-based Injectors
3.4.4. Classification based on Actuation Mechanism
3.4.4.1. Spring Loaded Jet Injectors
3.4.4.2. Battery Powdered Jet Injectors
3.4.4.3. Gas Powdered Jet Injectors
3.4.4.4. Laser Powered Injectors
3.4.4.5. Lorentz Force-based Injectors
3.5. Drug Delivery via Microneedle Devices
3.5.1. Types of Microneedle Devices
3.5.2. Advantages of Microneedle Devices
3.5.3. Fabrication of Microneedle Devices
3.5.4. Operating Mechanism of Microneedle Devices
3.6. Key Challenges related to Needle-Free Injection Systems and Microneedle Devices
3.7. Future Perspectives
4. NEEDLE-FREE INJECTION SYSTEMS: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Needle-Free Injection Systems: List of Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Geographical Location
4.3. Needle-Free Injection Systems: List of Available / Under Development Devices
4.3.1. Analysis by Type of Load
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Actuation Mechanism
4.3.4. Analysis by Status of Development
4.3.5. Analysis by Patent Availability
4.4. Needle-Free Injection Systems: Additional Information
4.4.1. Analysis by Target Disease Area
4.4.2. Analysis by Device Capacity
4.4.3. Analysis by Product Usability
4.5. Needle-Free Injection Systems: Recent Partnerships (2015-2019)
5. MICRONEEDLE DEVICES: MARKET OVERVIEW
5.1. Chapter Overview
5.2. Microneedle Devices: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.3. Microneedle Devices: List of Available / Under Development Devices
5.3.1. Analysis by Type of Microneedle
5.3.2. Analysis by Route of Administration
5.3.3. Analysis by Microneedle Length
5.3.4. Analysis by Target Disease Area
5.3.5. Analysis by Patent Availability
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Needle-Free Injection Systems
6.4.1. Spring-based Needle-Free Injection Systems
6.4.2. Gas-powered Needle-Free Injection Systems
6.4.3. Other Needle-Free Injection Systems
6.5. Product Competitiveness Analysis: Microneedle Devices
6.5.1. Hollow Microneedle Devices
6.5.2. Solid Microneedle Devices
6.5.3. Dissolving Microneedle Devices
6.5.4. Other Microneedle Devices
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Inovio Pharmaceuticals
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.2.1. Iject
7.2.2.2. Vitajet
7.2.2.3. Serojet
7.2.2.4. ZetaJet
7.2.2.5. Biojector 2000
7.2.2.6. Jupiter Jet
7.2.2.7. ID PEN
7.3. Medical International Technology
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.2.1. MED-JET MBX
7.3.2.2. MED-JET H4
7.3.2.3. MED-JET H-III
7.3.2.4. Meso-Jet
7.4. D'Antonio Consultants International
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.2.1. LectraJet HS
7.4.2.2. LectraJet M3 RA
7.4.2.3. LectraJet M4 RA
7.5. Enesi Pharma
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.2.1. ImplaVax
7.6. PharmaJet
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.2.1. PharmaJet Stratis
7.6.2.2. Tropis
7.7. Inolife Sciences
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.2.1. Inojex 30
7.7.2.2. Nanojex
7.8. NanoPass Technologies
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.2.1. MicronJet600
7.8.2.2. MicroPyramid
7.9. 3M
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.2.1. Hollow Microstructured Transdermal System
7.9.2.2. Solid Microstructured Transdermal System
7.10. Micropoint Technologies
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.2.1. Micropoint Patch
7.10.2.2. Hollow Microneedle Hub
7.12. Nemaura Pharma
7.12.1. Company Overview
7.12.2. Product Portfolio
7.12.2.1. Memspatch
7.12.2.2. Micro-Patch
7.12.2.3. Mycrolator
8. AC MATRIX
8.1. Chapter Overview
8.2. Overview of the AC Matrix
8.2.1. Strong Business Units
8.2.2. Average Business Units
8.2.3. Weak Business Units
8.3. Analytical Methodology
8.4. Comparison of Needle-Free Injection Systems and Microneedle Devices
8.5. Concluding Remarks
9. CASE STUDY: DRUG DELIVERY DEVICE CONTRACT MANUFACTURERS
9.1. Chapter Overview
9.2. Challenges Associated with Medical Device Manufacturing
9.3. Role of Contract Manufacturing Organizations (CMOs) in the Device Development
9.4. Regulatory Guidelines for Medical Devices
9.5. Medical Device CMOs Offering Services for Drug Delivery Devices
9.5.1. Analysis by Year of Establishment
9.5.2. Analysis by Company size
9.5.3. Analysis by Geographical Location
9.6. Geographical Distribution of Device Developers and Contract Service Providers
10. NEEDLE-FREE INJECTION SYSTEMS: LIKELY DRUG CANDIDATES
10.1. Chapter Overview
10.2. Marketed Drugs Candidates
10.2.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.1.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
10.3. Clinical Drug Candidates (Biologics)
10.3.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.3.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
10.4. Clinical Drug Candidates (Small Molecules)
10.4.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.4.4. Least Likely Candidates for Delivery via Needle-Free Injection Systems
11. MICRONEEDLE DEVICES: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs Candidates
11.2.1. Most Likely Candidates for Delivery via Microneedle Devices
11.2.2. Likely Candidates for Delivery via Microneedle Devices
11.2.3. Less Likely Candidates for Delivery via Microneedle Devices
11.2.4. Least Likely Candidates for Delivery via Microneedle Devices
11.3. Clinical Drug Candidates (Biologics)
11.3.1. Most Likely Candidates for Delivery via Microneedle Devices
11.3.2. Likely Candidates for Delivery via Microneedle Devices
11.3.3. Less Likely Candidates for Delivery via Microneedle Devices
11.3.4. Least Likely Candidates for Delivery via Microneedle Devices
11.4. Clinical Drug Candidates (Small Molecules)
11.4.1. Most Likely Candidates for Delivery via Microneedle Devices
11.4.2. Likely Candidates for Delivery via Microneedle Devices
11.4.3. Less Likely Candidates for Delivery via Microneedle Devices
11.4.4. Least Likely Candidates for Delivery via Microneedle Devices
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Needle-Free Injection Systems Market, 2019-2030
12.4. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
12.5. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
12.6. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
12.7. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
12.8. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
12.8.1 Needle-Free Injection Systems Market in North America, 2019-2030
12.8.1.1. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
12.8.1.2. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
12.8.1.3. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
12.8.1.4. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
12.8.2. Needle-Free Injection Systems Market in Europe, 2019-2030
12.8.2.1. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
12.8.2.2. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
12.8.2.3. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
12.8.2.4. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
12.8.3. Needle-Free Injection Systems Market in Asia, 2019-2030
12.8.3.1. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
12.8.3.2. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
12.8.3.3. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
12.8.3.4. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
12.8.4. Needle-Free Injection Systems Market in Rest of the World, 2019-2030
12.8.4.1. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
12.8.4.2. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
12.8.4.3. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
12.8.4.4. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
12.9. Global Microneedle Devices Market, 2019-2030
12.10. Global Microneedle Devices Market: Distribution by Type of Microneedle, 2019-2030
12.11. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
12.12. Global Microneedle Devices Market: Distribution by Regions, 2019-2030
12.12.1 Microneedle Devices Market in North America, 2019-2030
12.12.1.1. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2019-2030
12.12.1.2. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2019-2030
12.12.2. Microneedle Devices Market in Europe, 2019-2030
12.12.2.1. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2019-2030
12.12.2.2. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2019-2030
12.12.3. Microneedle Devices Market in Asia, 2019-2030
12.12.3.1. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
12.12.3.2. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
12.12.4. Microneedle Devices Market in Rest of the World, 2019-2030
12.12.4.1. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
12.12.4.2. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Vaxess Technologies
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Michael Schrader, CEO and Founder
13.3. Portal Instruments
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Patrick Anquetil, CEO
13.3. Innoture
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager
14. CONCLUDING REMARKS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Needle-Free Injection Systems: Advantages
Figure 3.2 Needle-Free Injection Systems: Key Components
Figure 3.3 Needle-Free Injection Systems: Stages of Drug Delivery
Figure 3.4 Drug Delivery via Microneedle Devices
Figure 3.5 Microneedle Devices: Fabrication Techniques
Figure 4.1 Needle-Free Injection System Developers: Distribution by Year of Establishment
Figure 4.2 Needle-Free Injection System Developers: Distribution by Company Size and Geographical Location
Figure 4.3 Needle-Free Injection Systems: Distribution by Type of Load
Figure 4.4 Needle-Free Injection Systems: Distribution by Route of Administration
Figure 4.5 Needle-Free Injection Systems: Distribution by Actuation Mechanism
Figure 4.6 Needle-Free Injection Systems: Distribution by Status of Development
Figure 4.7 Needle-Free Injection Systems: Distribution by Patent Availability
Figure 4.8 Needle-Free Injection Systems: Distribution by Target Disease Area
Figure 4.9 Needle-Free Injection Systems: Distribution by Type of Treatment
Figure 4.10 Needle-Free Injection Systems: Distribution by Device Capacity
Figure 4.11 Needle-Free Injection Systems: Distribution by Product Usability
Figure 4.12 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
Figure 5.1 Microneedle Device Developers: Distribution by Year of Establishment
Figure 5.2 Microneedle Device Developers: Distribution by Company Size and Geographical Location
Figure 5.3 Microneedle Devices: Distribution by Type of Microneedle Devices
Figure 5.4 Microneedle Devices: Distribution by Route of Administration
Figure 5.5 Microneedle Devices: Distribution by Microneedle Length
Figure 5.6 Microneedle Devices: Distribution by Target Disease Area
Figure 5.7 Microneedle Devices: Distribution by Type of Treatment
Figure 5.8 Microneedle Devices: Distribution by Patent Availability
Figure 6.1 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
Figure 6.2 Product Competitiveness Analysis: Compressed Gas-based Needle-Free Injection Systems
Figure 6.3 Product Competitiveness Analysis: Other Needle-Free Injection Systems
Figure 6.4 Product Competitiveness Analysis: Hollow Microneedle Devices
Figure 6.5 Product Competitiveness Analysis: Solid Microneedle Devices
Figure 6.6 Product Competitiveness Analysis: Dissolving Microneedle Devices
Figure 6.7 Product Competitiveness Analysis: Other Microneedle Devices
Figure 7.1 Inovio Pharmaceuticals: Annual Revenues, FY 2015-FY 2019 (USD Million)
Figure 7.2 3M: Annual Revenues, FY 2016-FY 2019 (USD Billion)
Figure 8.1 AC Matrix: Comparison of Needle-Free Injection Systems and Microneedle Devices
Figure 9.1 Challenges Associated with Medical Device Manufacturing
Figure 9.2 US FDA: Review / Approval Process
Figure 9.3 Medical Device Contract Manufacturing Organizations Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Figure 9.4 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Figure 9.5 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Region-wise)
Figure 9.6 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Country-wise)
Figure 9.7 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment, Geographical Location and Company Size
Figure 9.8 Geographical Analysis: Needle-Free Injection System / Microneedle Device Developers and Contract Manufacturers
Figure 12.1. Global Needle-Free Injection Systems Market, 2019-2030
Figure 12.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
Figure 12.3. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
Figure 12.4. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
Figure 12.5. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
Figure 12.6. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
Figure 12.7. Needle-Free Injection Systems Market in North America, 2019-2030
Figure 12.8. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
Figure 12.9. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
Figure 12.10. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
Figure 12.11. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
Figure 12.12. Needle-Free Injection Systems Market in Europe, 2019-2030
Figure 12.13. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
Figure 12.14. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
Figure 12.15. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
Figure 12.16. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
Figure 12.17. Needle-Free Injection Systems Market in Asia, 2019-2030
Figure 12.18. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
Figure 12.19. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
Figure 12.20. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
Figure 12.21. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
Figure 12.22. Needle-Free Injection Systems Market in Rest of the World, 20219-2030
Figure 12.23. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
Figure 12.24. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
Figure 12.25. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
Figure 12.26. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
Figure 12.27. Global Microneedle Devices Market, 2019-2030
Figure 12.28. Global Microneedle Devices Market: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.29. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
Figure 12.30. Global Microneedle Devices Market: Distribution by Regions, 2019-2030
Figure 12.31. Microneedle Devices Market in North America, 2019-2030
Figure 12.32. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.33. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2019-2030
Figure 12.34. Microneedle Devices Market in Europe, 2019-2030
Figure 12.35. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.36. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2019-2030
Figure 12.37. Microneedle Devices Market in Asia, 20219-2030
Figure 12.38. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.39. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
Figure 12.40. Microneedle Devices Market in Rest of the World, 20219-2030
Figure 12.41. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
Figure 12.42. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
Table 4.1. Needle-Free Injection Systems: List of Developers
Table 4.2. Needle-Free Injection Systems: List of Available / Under Development Devices
Table 4.2. Needle-Free Injection Systems: Additional Information
Table 4.3. Needle-Free Injection Systems: Partnerships and Collaborations, 2014-2019
Table 5.1. Microneedle Devices: List of Developers
Table 5.2. Microneedle Devices: List of Available / Under Development Devices
Table 7.1. List of Needle-Free Injection System and Microneedle Device Developers Profiled
Table 7.2. Inovio Pharmaceuticals: Company Snapshot
Table 7.3. Medical International Technology: Company Snapshot
Table 7.4. D'Antonio Consultants International: Company Snapshot
Table 7.5. Enesi Pharma: Company Snapshot
Table 7.6. PharmaJet: Company Snapshot
Table 7.7. Inolife Sciences: Company Snapshot
Table 7.8. NanoPass Technologies: Company Snapshot
Table 7.9. 3M: Company Snapshot
Table 7.10. Micropoint Technologies: Company Snapshot
Table 7.11. Nemaura Pharma: Company Snapshot
Table 9.1. List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 10.1. Marketed Molecules: Most Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.2. Marketed Molecules: Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.3. Marketed Molecules: Less Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.4. Marketed Molecules: Least Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.5. Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.6. Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.7. Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.8. Clinical Drug Candidates (Biologics): Least Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.9. Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.10. Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.11. Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Needle-Free Injection Systems
Table 10.12. Clinical Drug Candidates (Small Molecules): Least Likely Candidates for Delivery via Needle-Free Injection Systems
Table 11.1. Marketed Molecules: Most Likely Candidates for Delivery via Microneedle Devices
Table 11.2. Marketed Molecules: Likely Candidates for Delivery via Microneedle Devices
Table 11.3. Marketed Molecules: Less Likely Candidates for Delivery via Microneedle Devices
Table 11.4. Marketed Molecules: Least Likely Candidates for Delivery via Microneedle Devices
Table 11.5. Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Microneedle Devices
Table 11.6. Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Microneedle Devices
Table 11.7. Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Microneedle Devices
Table 11.8. Clinical Drug Candidates (Biologics): Least Likely Candidates for Delivery via Microneedle Devices
Table 11.9. Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Microneedle Devices
Table 11.10. Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Microneedle Devices
Table 11.11. Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Microneedle Devices
Table 11.12. Clinical Drug Candidates (Small Molecules): Least Likely Candidates for Delivery via Microneedle Devices
Table 13.1. Innoture: Company Snapshot
Table 13.2. Portal Instruments: Company Snapshot
Table 13.3. Vaxess Technologies: Company Snapshot
Table 15.1. Needle-Free Injection System Developers: Distribution by Year of Establishment
Table 15.2. Needle-Free Injection Systems Developers: Distribution by Company Size and Geographical Location
Table 15.3. Needle-Free Injection Systems: Distribution by Type of Load
Table 15.4. Needle-Free Injection Systems: Distribution by Route of Administration
Table 15.5. Needle-Free Injection Systems: Distribution by Actuation Mechanism
Table 15.6. Needle-Free Injection Systems: Distribution by Status of Development
Table 15.7. Needle-Free Injection Systems: Distribution by Patent Availability
Table 15.8. Needle-Free Injection Systems: Distribution by Target Disease Area
Table 15.9. Needle-Free Injection Systems: Distribution by Type of Treatment
Table 15.10. Needle-Free Injection Systems: Distribution by Device Capacity
Table 15.11. Needle-Free Injection Systems: Distribution by Product Usability
Table 15.12. Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
Table 15.13. Microneedle Devices: Distribution by Year of Establishment
Table 15.14. Microneedle Devices: Distribution by Company Size and Geographical Location
Table 15.15. Microneedle Devices: Distribution by Type of Microneedle Devices
Table 15.16. Microneedle Devices: Distribution by Route of Administration
Table 15.17. Microneedle Devices: Distribution by Microneedle Length
Table 15.18. Microneedle Devices: Distribution by Target Disease Area
Table 15.19. Microneedle Devices: Distribution by Type of Treatment
Table 15.20. Microneedle Devices: Distribution by Patent Availability
Table 15.21. Inovio Pharmaceuticals: Annual Revenues, FY 2015-FY 2019 (USD Million)
Table 15.22. 3M: Annual Revenues, FY 2016-FY 2019 (USD Billion)
Table 15.23. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Table 15.24. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Table 15.25. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Region-wise)
Table 15.26. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Geographical Location (Country-wise)
Table 15.27. Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment, Geographical Location and Company Size
Table 15.28. Global Needle-Free Injection Systems Market, 2019-2030
Table 15.29. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
Table 15.30. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
Table 15.31. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
Table 15.32. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
Table 15.33. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
Table 15.34. Needle-Free Injection Systems Market in North America, 2019-2030
Table 15.35. Needle-Free Injection Systems Market in North America: Distribution by Region
Table 15.36. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
Table 15.37. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
Table 15.38. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
Table 15.39. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
Table 15.40. Needle-Free Injection Systems Market in Europe, 2019-2030
Table 15.41. Needle-Free Injection Systems Market in Europe: Distribution by Actuation Mechanism, 2019-2030
Table 15.42. Needle-Free Injection Systems Market in Europe: Distribution by Route of Administration, 2019-2030
Table 15.43. Needle-Free Injection Systems Market in Europe: Distribution by Target Disease Indication, 2019-2030
Table 15.44. Needle-Free Injection Systems Market in Europe: Distribution by Product Usability, 2019-2030
Table 15.45. Needle-Free Injection Systems Market in Asia, 2019-2030
Table 15.46. Needle-Free Injection Systems Market in Asia: Distribution by Region
Table 15.47. Needle-Free Injection Systems Market in Asia: Distribution by Actuation Mechanism, 2019-2030
Table 15.48. Needle-Free Injection Systems Market in Asia: Distribution by Route of Administration, 2019-2030
Table 15.49. Needle-Free Injection Systems Market in Asia: Distribution by Target Disease Indication, 2019-2030
Table 15.50. Needle-Free Injection Systems Market in Asia: Distribution by Product Usability, 2019-2030
Table 15.51. Needle-Free Injection Systems Market in Rest of the World, 20219-2030
Table 15.52. Needle-Free Injection Systems Market in Rest of the World: Distribution by Actuation Mechanism, 2019-2030
Table 15.53. Needle-Free Injection Systems Market in Rest of the World: Distribution by Route of Administration, 2019-2030
Table 15.54. Needle-Free Injection Systems Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
Table 15.55. Needle-Free Injection Systems Market in Rest of the World: Distribution by Product Usability, 2019-2030
Table 15.56. Global Microneedle Devices Market, 2019-2030
Table 15.57. Global Microneedle Devices Market: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.58. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
Table 15.59. Global Microneedle Devices Market: Distribution by Regions, 2023-2030
Table 15.60. Microneedle Devices Market in North America, 2023-2030
Table 15.61. Microneedle Devices Market in North America: Distribution by Region
Table 15.62. Microneedle Devices Market in North America: Distribution by Types of Microneedle Devices, 2023-2030
Table 15.63. Microneedle Devices Market in North America: Distribution by Target Disease Indication, 2023-2030
Table 15.64. Microneedle Devices Market in Europe, 2023-2030
Table 15.65. Microneedle Devices Market in Europe: Distribution by Types of Microneedle Devices, 2023-2030
Table 15.66. Microneedle Devices Market in Europe: Distribution by Target Disease Indication, 2023-2030
Table 15.67. Microneedle Devices Market in Asia, 2023-2030
Table 15.68. Microneedle Devices Market in Asia: Distribution by Region
Table 15.69. Microneedle Devices Market in Asia: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.70. Microneedle Devices Market in Asia: Distribution by Target Disease Indication, 2019-2030
Table 15.71. Microneedle Devices Market in Rest of the World, 2019-2030
Table 15.72. Microneedle Devices Market in Rest of the World: Distribution by Types of Microneedle Devices, 2019-2030
Table 15.73. Microneedle Devices Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030
The following companies and organizations have been mentioned in the report:
Source 1: www.who.int/chp/chronic_disease_report/part1/en/index1.html
Source 2: www.who.int/occupational_health/activities/1anaism.pdf
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES